CureVac的股东在2025年11月26日批准增加资本, 以提升其财政实力及MRNA研究。 CureVac's shareholders approved a capital increase on Nov. 26, 2025, to boost its financial strength and mRNA research.

CureVac报告了其2025年11月26日举行的特别大会的结果,确认股东批准拟议的资本增加。 CureVac reported the results of its extraordinary general meeting held on November 26, 2025, confirming shareholder approval for a proposed capital increase. 投票支持该公司努力加强其财务状况并推进其MRNA技术管道。 The vote supports the company’s efforts to strengthen its financial position and advance its mRNA technology pipeline. 关于表决票数或百分比的具体细节没有在公告中披露。 Specific details on the number of votes or percentages were not disclosed in the announcement.